Article tools
Author information

Research Article

AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins.

J G de la Asunción, M L del Olmo, J Sastre, A Millán, A Pellín, F V Pallardó and J Viña

Departamento de Fisiología, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.

AIDS patients who receive zidovudine (AZT) frequently suffer from myopathy. This has been attributed to mitochondrial (mt) damage, and specifically to the loss of mtDNA. This study examines whether AZT causes oxidative damage to DNA in patients and to skeletal muscle mitochondria in mice, and whether this damage may be prevented by supranutritional doses of antioxidant vitamins. Asymptomatic HIV-infected patients treated with AZT have a higher urinary excretion (355+/-100 pmol/kg/d) of 8-oxo-7, 8-dihydro-2'-deoxyguanosine (8-oxo-dG) (a marker of oxidative damage to DNA) than untreated controls (asymptomatic HIV-infected patients) (182+/-29 pmol/kg/d). This was prevented (110+/-79 pmol/kg/d) by simultaneous oral treatment with AZT plus antioxidant vitamins (C and E). Mice treated with AZT also had a significantly higher urinary excretion of 8-oxo-dG than controls. Skeletal muscle mtDNA of mice treated with AZT had more 8-oxo-dG than controls. mt lipoperoxidation was also increased and skeletal muscle glutathione was oxidized. These effects may be due to an increased peroxide production by muscle mitochondria of AZT-treated animals. Dietary supplements with vitamins C and E at supranutritional doses protect against oxidative damage to skeletal muscle mitochondria caused by AZT.


Articles that cite this article:

Oxidant Stress and Peripheral Neuropathy During Antiretroviral Therapy
Todd Hulgan, Michael Hughes, Xin Sun, Laura M. Smeaton, Erin Terry, Gregory K. Robbins, Robert W. Shafer, David B. Clifford, Grace A. Mccomsey, Jeffery A. Canter
Journal of Acquired Immune Deficiency Syndrome 42(4):450. doi:10.1097/01.qai.0000226792.16216.1c [CrossRef]

Transplacental drug transfer and frequency ofTk andHprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine
Linda S. Von tungeln, Lee D. Williams, Daniel R. Doerge, Joseph G. Shaddock, Lynda J. Mcgarrity, Suzanne M. Morris, Roberta A. Mittelstaedt, Robert H. Heflich, Frederick A. Beland
Environ Mol Mutagen 48(3-4):258. doi:10.1002/em.20237 [CrossRef]

Mitochondria as the target for mildronate's protective effects in azidothymidine (AZT)‐induced toxicity of isolated rat liver mitochondria
Jolanta Pupure, Maria A. S. Fernandes, Maria S. Santos, António J. M. Moreno, Ivars Kalvinsh, Vija Klusa, Catarina R. Oliveira
Cell Biochem Funct 26(5):620. doi:10.1002/cbf.1486 [CrossRef]

Antioxidant vitamins and cancer risk: is oxidative damage to DNA a relevant biomarker?
Steffen Loft, Peter Møller, Marcus S. Cooke, Rafal Rozalski, Ryszard Olinski
Eur J Nutr 47(s2):19. doi:10.1007/s00394-008-2004-0 [CrossRef]

Mechanisms of Zidovudine-Induced Mitochondrial Toxicity and Myopathy
Erin R. Scruggs, Amie J. Dirks naylor
Pancreatology 82(2):83. doi:10.1159/000134943 [CrossRef]